Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

T2 BIOSYSTEMS, INC.

(TTOO)
  Report
Delayed Nasdaq  -  03:59 2022-12-02 pm EST
1.690 USD   -1.17%
11/25T2 Biosystems, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
11/15T2 Biosystems : Webcast
PU
11/14T2 BIOSYSTEMS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/28/2022 11/29/2022 11/30/2022 12/01/2022 12/02/2022 Date
1.65(c) 1.65(c) 1.66(c) 1.71(c) 1.69(c) Last
110 762 123 645 76 762 136 848 104 408 Volume
-7.31% 0.00% +0.61% +3.01% -1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 22,3 M - -
Net income 2022 -66,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,23x
Yield 2022 -
Sales 2023 27,0 M - -
Net income 2023 -53,3 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,28x
Yield 2023 -
Capitalization 12,4 M 12,4 M -
Capi. / Sales 2022 0,56x
Capi. / Sales 2023 0,46x
Nbr of Employees 182
Free-Float 97,7%
More Financials
Company
T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The Company is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular... 
More about the company
Ratings of T2 Biosystems, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about T2 BIOSYSTEMS, INC.
11/25T2 Biosystems, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
AQ
11/15T2 Biosystems : Webcast
PU
11/14T2 BIOSYSTEMS, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/10T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/10T2 Biosystems : Q3 Earnings Snapshot
AQ
11/10Transcript : T2 Biosystems, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Earnings Flash (TTOO) T2 BIOSYSTEMS Reports Q3 Loss $-2.95, vs. Street Est of $-2.05
MT
11/10Earnings Flash (TTOO) T2 BIOSYSTEMS Reports Q3 Revenue $3.7M, vs. Street Est of $4.7M
MT
11/10T2 Biosystems Announces Third Quarter 2022 Financial Results
AQ
11/10T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
AQ
11/09T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital ..
AQ
11/08T2 Biosystems : Webcast
PU
11/07T2 Biosystems, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure,..
AQ
11/07T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, ..
CI
11/07HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics P..
AQ
More news
News in other languages on T2 BIOSYSTEMS, INC.
11/10T2 Biosystems, Inc. annonce ses résultats financiers pour le troisième trimestre et les..
11/07T2 Biosystems, Inc. annonce la démission d'Alec Barclay au poste de directeur des opéra..
10/20T2 Biosystems, Inc. lance des études pour ajouter Acinetobacter Baumannii au panel T2Ba..
10/13T2 Biosystems prévoit de commencer la commercialisation et la vente du test de diagnost..
10/13T2 Biosystems, Inc. annonce son intention de commercialiser un test de diagnostic pour ..
More news
Analyst Recommendations on T2 BIOSYSTEMS, INC.
More recommendations
Chart T2 BIOSYSTEMS, INC.
Duration : Period :
T2 Biosystems, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends T2 BIOSYSTEMS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 1,69 $
Average target price 2,35 $
Spread / Average Target 39,1%
EPS Revisions
Managers and Directors
John J. Sperzel Chairman, President & Chief Executive Officer
John M. Sprague Chief Financial Officer
Aparna Ahuja Chief Medical Officer
Roger Smith Vice President-Science, Research & Development
Alec Barclay Chief Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
T2 BIOSYSTEMS, INC.-93.45%12
THERMO FISHER SCIENTIFIC-15.62%220 754
DANAHER CORPORATION-16.65%199 032
INTUITIVE SURGICAL, INC.-23.60%95 552
BOSTON SCIENTIFIC CORPORATION8.57%64 841
SIEMENS HEALTHINEERS AG-21.63%58 421